Laboratorios Servier

Servier is a global independent pharmaceutical group governed by a non-profit foundation, headquartered in Suresnes, France. The company operates across five primary therapeutic areas: oncology, cardiovascular diseases, immune-inflammatory diseases, neuropsychiatric disorders, and metabolic diseases. Servier has undergone a significant strategic shift toward oncology, bolstered by the acquisitions of Shire's oncology business and Agios Pharmaceuticals' oncology portfolio. The group is unique in its governance structure, reinvesting over 20% of its brand-name revenue into research and development annually. With a commercial presence in over 150 countries, Servier maintains a robust pipeline of small molecules and biologics, particularly focusing on targeted therapies for hard-to-treat cancers. Key products include Tibsovo for IDH1-mutant cancers and Lonsurf for gastrointestinal malignancies.